News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement

Denise Dixon

Advertisement

Global Chief Operating Officer, Diligent Health Solutions

Articles by Denise Dixon

Virtual Medical Affairs Audits: A Viable Alternative

ByAlena Galante,Denise Dixon
November 10th 2022

Virtual audits proving to be beneficial post-COVID despite continuing challenges.

Advertisement

Latest Updated Articles

  • Virtual Medical Affairs Audits: A Viable Alternative
    Virtual Medical Affairs Audits: A Viable Alternative

    Published: November 10th 2022 | Updated:



Advertisement
Advertisement

Trending on PharmExec

1

J.P. Morgan 2026: Pfizer’s Pivot from Covid to Pipeline Execution

2

JP Morgan 2026: Bristol Myers Squibb Focuses on the Next Decade

3

Johnson & Johnson Announces Second $2 Billion Manufacturing Facility in North Carolina

4

Pharmaceutical Executive Daily: Johnson & Johnson Continues $55 Billion Manufacturing Investment

5

How is Re-Vana Using its Sustained-Delivery Hydrogel Technology to Position Itself as a Long-Term Partner at the 2026 J.P. Morgan Healthcare Conference?

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us